New Awards Program Focused on Cardiovascular Risk in Patients with Diabetes

PfizerPfizer and the European Foundation for the Study of Diabetes (EFSD) announced today, at the European Association for the Study of Diabetes (EASD) Annual Meeting, the development of a new awards program which will provide research grants to support European research around understanding and reducing cardiovascular risk in patients with diabetes.

Grants will be awarded for, but not limited to, research focusing on fostering a clearer understanding of the best cardiovascular risk-reduction strategies, such as educational programs, risk- assessment tools, screenings and clinical interventions.

"Pfizer is proud to partner with the EFSD on this new research initiative," said Dr. Lance Berman, senior medical director, Pfizer. "As part of our commitment to the care of patients with diabetes, Pfizer is dedicated to supporting research that will help identify ways to reduce these risks, further our understanding of optimal treatment options, and ultimately improve the lives of the people with diabetes."

Researchers who are interested in applying for a grant through this new program will be able to submit applications beginning in January 2008. Specific instructions for how to apply will be published in an upcoming issue of Diabetologia, the journal of the EASD, and will also be available on the Pfizer and EFSD websites. The deadline for submissions is March 2008 and recipients of the grants will be announced in June 2008.

"We are excited about this new grant program and partnership with Pfizer," said Professor Philippe Halban, EFSD chairman. "While the EFSD has several different grant programs, this is the first research program partnership to focus on understanding and reducing cardiovascular risk in people with diabetes. This will help the medical community better understand how to prevent the devastating effects that cardiovascular disease has on the lives of the people with diabetes."

Diabetes currently affects an estimated 230 million people worldwide. The most life-threatening consequences of diabetes are heart disease and stroke, with more than 65 percent of deaths in people with diabetes being attributed to heart and cardiovascular disease. Additionally, more than twice as many people with diabetes suffer from heart disease compared to those without diabetes.

For further information, visit www.pfizer.com.

About European Foundation for the Study of Diabetes (EFSD)
In 1999, the European Association for the Study of Diabetes (EASD) increased its commitment to stimulate diabetes research in Europe by creating the European Foundation for the Study of Diabetes (EFSD). The Foundation is closely related to the EASD; it is governed exclusively by the Executive Committee of the EASD, which itself is under the close supervision of the EASD Council and the General Assembly of the EASD. EFSD operates on a strictly non-profit basis under the control of the relevant authorities for charity and taxation in order to support diabetes research. The EASD, as an academic non-profit association, benefits from the possibilities offered by the legal status of its Foundation to advance diabetes research by various methods. For more informatin, visit www.europeandiabetesfoundation.org.

Most Popular Now

Swissmedic begins rolling review of Moderna's mRNA…

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...

Moderna's COVID-19 vaccine candidate meets its pri…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...

Pfizer and BioNTech conclude Phase 3 study of COV…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based...

Pfizer and BioNTech to submit Emergency Use Author…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authori...

Phase 2 trial of Oxford COVID-19 vaccine in health…

The UK's vaccine against SARS-CoV-2 shows similar safety and immunogenicity results in healthy older adults (aged 56 years and over) to those seen in adults aged 18-55 ye...

Lilly's neutralizing antibody bamlanivimab (LY-CoV…

The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY) investigational neutralizing antibody bamlan...

Chinese vaccine candidate based on inactivated SAR…

Results from an early-phase randomised clinical trial of a Chinese vaccine candidate based on the inactivated whole SARS-CoV-2 virus (CoronaVac) are published in The Lanc...

Medicago and GSK announce start of Phase 2/3 clini…

Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK have announced the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate f...

European Commission approves contract with BioNTec…

Today, the European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses ...

Pre-existing coronavirus antibodies could help pro…

Researchers at the Francis Crick Institute and University College London have found that some antibodies, created by the immune system during infection with common cold c...

Fluvoxamine may prevent serious illness in COVID-1…

In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Me...

The Sputnik V COVID-19 vaccine efficacy amounted t…

The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Rus...